EUVIMEDEUVIMED entdecken
Crossref

Posaconazole in Clinical Practice: A Narrative Review of Current Evidence and Expert Recommendations

Halis Akalın, Sevtap Arıkan-Akdağlı, Muhlis Cem Ar, Alpay Azap, Gülçin Telli-Dizman, Şiran Keske, Gökhan Metan, Vildan Özkocaman, Rabin Saba, Ömrüm Uzun, Murat Akova

Infectious Diseases and Clinical Microbiology · 11.11.2026 · 1

DOI: 10.36519/idcm.2026.1128 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Infectious Diseases and Clinical Microbiology, online erschienen am 11.11.2026. Verfasst von Halis Akalın und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Posaconazole is a broad-spectrum antifungal agent used to manage invasive fungal infections (IFIs), particularly in high-risk immunocompromised patients. It is active against a range of fungal pathogens, including Candida spp., Aspergillus spp., and Mucorales. The introduction of delayed-release tablets and intravenous formulations has significantly expanded its clinical utility by overcoming the pharmacokinetic limitations of the original oral suspension. Randomized controlled trials provide strong evidence supporting posaconazole as the preferred agent for primary antifungal prophylaxis in patients with acute myeloid leukemia, myelodysplastic syndromes, and allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. It has demonstrated superior efficacy over fluconazole and itraconazole in reducing the incidence of IFIs and associated mortality, earning strong recommendations in major international guidelines, including those of the European Conference on Infections in Leukemia (ECIL) and the Infectious Diseases Society of America (IDSA). Beyond prophylaxis, posaconazole’s role in treatment continues to expand. A pivotal randomized controlled trial has demonstrated its non-inferiority to voriconazole as first-line therapy for invasive aspergillosis, positioning it as an important first-line treatment option. Posaconazole also remains a key agent for salvage therapy or as an alternative for patients intolerant or refractory to other first-line agents such as liposomal amphotericin B. Its well-documented tolerability profile and availability in flexible dosing formulations support its use in prolonged treatment courses and complex clinical scenarios. The clinical landscape continues to evolve with the emergence of new at-risk populations, including patients receiving novel cancer immunotherapies and those affected by viral-associated fungal infections such as coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis. Despite these advances, significant practical challenges persist, including formulation-dependent pharmacokinetics, clinically relevant drug-drug interactions, and ongoing uncertainty regarding the role of therapeutic drug monitoring. This narrative review summarizes current evidence and offers expert experience for clinicians navigating the complexities of posaconazole use in both prophylaxis and treatment in daily clinical practice.

Zitieren

APA

Akalın, H., Arıkan-Akdağlı, S., Ar, M. C., Azap, A., Telli-Dizman, G., Keske, Ş., Metan, G., Özkocaman, V., Saba, R., Uzun, Ö., & Akova, M. (2026). Posaconazole in Clinical Practice: A Narrative Review of Current Evidence and Expert Recommendations. Infectious Diseases and Clinical Microbiology, 1. https://doi.org/10.36519/idcm.2026.1128

Vancouver

Akalın H, Arıkan-Akdağlı S, Ar MC, Azap A, Telli-Dizman G, Keske Ş, et al. Posaconazole in Clinical Practice: A Narrative Review of Current Evidence and Expert Recommendations. Infectious Diseases and Clinical Microbiology. 2026:1. doi:10.36519/idcm.2026.1128

BibTeX
@article{Akaln2026,
  author = {Akalın, Halis and Arıkan-Akdağlı, Sevtap and Ar, Muhlis Cem and Azap, Alpay and Telli-Dizman, Gülçin and Keske, Şiran and Metan, Gökhan and Özkocaman, Vildan and Saba, Rabin and Uzun, Ömrüm and Akova, Murat},
  title = {Posaconazole in Clinical Practice: A Narrative Review of Current Evidence and Expert Recommendations},
  journal = {Infectious Diseases and Clinical Microbiology},
  year = {2026},
  pages = {1},
  doi = {10.36519/idcm.2026.1128}
}
Kostenlos starten →